Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Pasithea Therapeutics Corp. is a biotechnology company focused on developing novel treatments for psychiatric and neurological disorders, particularly through its proprietary platform targeting the endocannabinoid system. The company operates primarily in the United States and Europe, leveraging its unique research capabilities to differentiate its product offerings in a competitive landscape.
Pasithea generates revenue primarily through partnerships with pharmaceutical companies for the development of cannabinoid-based therapies. Its competitive advantage lies in its proprietary research platform and strong intellectual property portfolio, which allows it to command premium pricing for its innovative solutions.
Progress in clinical trials for its lead candidate targeting depression
Partnership announcements with larger pharmaceutical companies
Regulatory approvals for its drug candidates
Market sentiment around the cannabinoid therapy sector
Regulatory changes impacting drug approval processes
Technological disruption in drug development methodologies
Emergence of new competitors in the cannabinoid therapy space
Potential for larger pharmaceutical companies to develop similar therapies
High cash burn rate due to extensive R&D activities
Dependence on external funding sources for operational sustainability
moderate - The biotechnology sector can be sensitive to economic cycles, particularly in terms of funding availability and consumer spending on healthcare.
Higher interest rates could increase the cost of capital for Pasithea, affecting its ability to finance R&D activities and potentially delaying product development timelines.
minimal - The company currently has no debt, reducing its exposure to credit market fluctuations.
growth - Investors are likely attracted to the potential for high returns from innovative therapies in a growing market.
high - The stock has exhibited high volatility due to its speculative nature and reliance on clinical trial outcomes.
